Tuis600664 • SHA
add
Harbin Pharmaceutical Group Co., Ltd.
Vorige sluiting
¥3,73
Dagwisseling
¥3,65 - ¥3,78
Jaarwisseling
¥2,41 - ¥4,26
Markkapitalisasie
9,29 mjd CNY
Gemiddelde volume
48,78 m
P/V-verhouding
15,63
Dividend-opbrengs
-
Primêre beurs
SHA
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (CNY) | Sep. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 4,11 mjd | 8,54% |
Bedryfskoste | 833,10 m | 0,85% |
Netto inkomste | 164,90 m | 52,98% |
Netto winsgrens | 4,01 | 41,20% |
Wins per aandeel | — | — |
EBITDA | 318,87 m | 26,26% |
Effektiewe belastingkoers | 23,46% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (CNY) | Sep. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 3,13 mjd | 13,03% |
Totale bates | 14,27 mjd | 2,51% |
Totale aanspreeklikheid | 8,32 mjd | -3,45% |
Totale ekwiteit | 5,95 mjd | — |
Uitstaande aandele | 2,52 mjd | — |
Prys om te bespreek | 1,80 | — |
Opbrengs op bates | 4,51% | — |
Opbrengs op kapitaal | 8,25% | — |
Kontantvloei
Netto kontantverandering
| (CNY) | Sep. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | 164,90 m | 52,98% |
Kontant van bedrywe | 105,03 m | -61,67% |
Kontant van beleggings | -35,33 m | 74,29% |
Kontant van finansiering | -173,45 m | -5 358,43% |
Netto kontantverandering | -104,01 m | -174,49% |
Beskikbare kontantvloei | -77,99 m | 22,01% |
Meer oor
Harbin Pharmaceutical Group Co., Ltd. is a Chinese partially state-owned company engaged in the research & development, manufacture, and sale of pharmaceutical products. HPGC medication offerings include traditional Chinese medicine and biopharmaceuticals; its main offerings include antibiotics, including amoxicillin and penicillin, and dietary supplements, including zinc gluconate and calcium gluconate.
The company owns both Renmintongtai, a drugstore chain and medical wholesaler for the domestic market, and GNC, a U.S.-based international retailer of supplements and wellness products. Wikipedia
Gestig
1988
Webwerf
Werknemers
9 853
